Nolotil (Metamizole Magnesium)

Metamizole magnesium, the active ingredient in Nolotil, is a pyrazolone analgesic presented as an injectable solution for intramuscular and intravenous use. It treats pain and fever, including postoperative pain and colic, in adult patients.\n\nGNH India supplies Nolotil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to strict quality standards.

Nolotil (metamizole magnesium) is employed for acute pain and fever management across several clinical situations.\n\n- Pain: provides rapid analgesia for moderate to severe acute pain.\n- Fever: reduces elevated body temperature in febrile states.\n- Post‑operative pain: controls pain following surgical procedures.\n- Colic: alleviates visceral pain associated with intestinal or biliary colic.

Metamizole magnesium may cause a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Nausea: mild gastrointestinal upset.\n- Vomiting: occasional emesis.\n- Dizziness: feeling of light‑headedness.\n- Injection site reactions: pain or erythema at the administration site.\n\nSerious or Rare Side Effects:\n- Agranulocytosis: severe reduction in white blood cells.\n- Anaphylaxis: acute allergic reaction with potential airway compromise.\n- Stevens‑Johnson syndrome: rare severe skin reaction.

Before using Nolotil, clinicians should consider several safety measures.\n\n- Indication assessment: confirm pain or fever requiring parenteral therapy before use.\n- Blood monitoring: perform regular complete blood count to detect agranulocytosis.\n- Renal function: evaluate kidney function in patients with impairment.\n- Concomitant drugs: avoid use with other myelotoxic agents.\n- Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.\n- Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and do not freeze.

Metamizole magnesium can interact with several medicines, altering efficacy or safety.\n\nMajor Interactions (Avoid):\n- Anticoagulants: may increase bleeding risk.\n- Immunosuppressants (e.g., azathioprine): heightened risk of bone marrow suppression.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: additive gastrointestinal irritation.\n- ACE inhibitors: possible potentiation of hypotensive effects.\n- Diuretics: may enhance risk of electrolyte imbalance.